BiVictriX Therapeutics plc announced that Non-Executive Director, Iain Ross, is stepping down from the board with immediate effect to pursue other interests. A Nomination Committee, consisting of Non-Executive Directors and chaired by Dr. Michael Kauffman, will initiate a search for Iain's replacement with appropriate skills to help move the Company forward, in anticipation of its first clinical trials in patients with Acute Myeloid Leukaemia.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
10 GBX | 0.00% | -13.04% | -4.76% |
Apr. 17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
Apr. 17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.76% | 10.48M | |
+41.79% | 54.04B | |
-0.56% | 41.92B | |
+49.39% | 41.96B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+24.91% | 12.19B | |
+29.60% | 12.28B |
- Stock Market
- Equities
- BVX Stock
- News BiVictriX Therapeutics Plc
- Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board